ID   SK-GT-4
AC   CVCL_2195
SY   SKGT4; SK4
DR   EFO; EFO_0001237
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1011
DR   BioSample; SAMN03473395
DR   cancercelllines; CVCL_2195
DR   Cell_Model_Passport; SIDM00483
DR   Cosmic; 1599346
DR   Cosmic-CLP; 1503365
DR   DepMap; ACH-001654
DR   DSMZ; ACC-712
DR   DSMZCellDive; ACC-712
DR   ECACC; 11012007
DR   EGA; EGAS00001000978
DR   GDSC; 1503365
DR   GEO; GSE2144
DR   GEO; GSE13376
DR   GEO; GSM1374878
DR   GEO; GSM1670431
DR   IARC_TP53; 4079
DR   PharmacoDB; SKGT4_1389_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54953662
RX   PubMed=7665247;
RX   PubMed=8334620;
RX   PubMed=11520067;
RX   PubMed=20075370;
RX   PubMed=20139130;
RX   PubMed=23795680;
RX   PubMed=26317542;
RX   PubMed=27397505;
RX   PubMed=27594985;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Population: Caucasian.
CC   Doubling time: 39 hours (PubMed=8334620); ~30-35 hours (DSMZ=ACC-712).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=27594985; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln100Ter (c.298C>T); ClinVar=VCV000634707; Zygosity=Homozygous (PubMed=20075370; Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.11%; Native American=1.08%; East Asian, North=1.62%; East Asian, South=0%; South Asian=7.99%; European, North=27.72%; European, South=59.48% (PubMed=30894373).
CC   Caution: TP53 mutation indicated incorrectly as being at p.Arg175His (c.524G>A) in PubMed=7665247.
CC   Misspelling: SJGT4; GEO=GSM337727.
CC   Derived from site: In situ; Esophagus, distal; UBERON=UBERON_0013473.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ; PubMed=20075370
ST   Amelogenin: X
ST   CSF1PO: 11,15
ST   D13S317: 9,10
ST   D16S539: 11,12,13
ST   D18S51: 14
ST   D19S433: 13,14
ST   D21S11: 31.2
ST   D2S1338: 16,19
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 7,11
ST   D8S1179: 13
ST   FGA: 22,23
ST   Penta D: 9
ST   Penta E: 7
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 17,19
DI   NCIt; C4025; Esophageal adenocarcinoma
DI   ORDO; Orphanet_99976; Adenocarcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   89Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 34
//
RX   PubMed=7665247; DOI=10.1002/ijc.2910640109;
RA   Nabeya Y., Loganzo F. Jr., Maslak P., Lai L., de Oliveira A.R.,
RA   Schwartz G.K., Blundell M.L., Altorki N.K., Kelsen D.P., Albino A.P.;
RT   "The mutational status of p53 protein in gastric and esophageal
RT   adenocarcinoma cell lines predicts sensitivity to chemotherapeutic
RT   agents.";
RL   Int. J. Cancer 64:37-46(1995).
//
RX   PubMed=8334620; DOI=10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L;
RA   Altorki N.K., Schwartz G.K., Blundell M.L., Davis B.M., Kelsen D.P.,
RA   Albino A.P.;
RT   "Characterization of cell lines established from human gastric-esophageal
RT   adenocarcinomas. Biologic phenotype and invasion potential.";
RL   Cancer 72:649-657(1993).
//
RX   PubMed=11520067; DOI=10.1006/bbrc.2001.5400;
RA   Kan T., Shimada Y., Sato F., Maeda M., Kawabe A., Kaganoi J.-i.,
RA   Itami A., Yamasaki S., Imamura M.;
RT   "Gene expression profiling in human esophageal cancers using cDNA
RT   microarray.";
RL   Biochem. Biophys. Res. Commun. 286:792-801(2001).
//
RX   PubMed=20075370; DOI=10.1093/jnci/djp499;
RA   Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P.,
RA   Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K.,
RA   Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H.,
RA   Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.;
RT   "Verification and unmasking of widely used human esophageal
RT   adenocarcinoma cell lines.";
RL   J. Natl. Cancer Inst. 102:271-274(2010).
//
RX   PubMed=20139130; DOI=10.1093/carcin/bgq036;
RA   Duggan S.P., Behan F.M., Kirca M., Smith S.M., Reynolds J.V., Long A.,
RA   Kelleher D.P.;
RT   "An integrative genomic approach in oesophageal cells identifies TRB3
RT   as a bile acid responsive gene, downregulated in Barrett's oesophagus,
RT   which regulates NF-kappaB activation and cytokine levels.";
RL   Carcinogenesis 31:936-945(2010).
//
RX   PubMed=23795680; DOI=10.1111/dote.12095;
RA   Boonstra J.J., Tilanus H.W., Dinjens W.N.M.;
RT   "Translational research on esophageal adenocarcinoma: from cell line
RT   to clinic.";
RL   Dis. Esophagus 28:90-96(2015).
//
RX   PubMed=26317542; DOI=10.18632/oncotarget.4540;
RA   Chen Q.-R., Song S.-M., Wei S.-Z., Liu B., Honjo S., Scott A.,
RA   Jin J.-K., Ma L., Zhu H.-T., Skinner H.D., Johnson R.L., Ajani J.A.;
RT   "ABT-263 induces apoptosis and synergizes with chemotherapy by
RT   targeting stemness pathways in esophageal cancer.";
RL   Oncotarget 6:25883-25896(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27594985; DOI=10.12688/f1000research.7033.1;
RA   Contino G., Eldridge M.D., Secrier M., Bower L., Elliott R.F., Weaver J.,
RA   Lynch A.G., Edwards P.A.W., Fitzgerald R.C.;
RT   "Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.";
RL   F1000Research 5:1336.1-1336.12(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//